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Abstract 
Microbubbles have shown potential as intralymphatic ultrasound contrast agents while nanopar-
ticle-loaded microbubbles are increasingly investigated for ultrasound-triggered drug and gene 
delivery. To explore whether mRNA-nanoparticle loaded microbubbles could serve as 
theranostics for detection of and mRNA transfer to the lymph nodes, we investigate the behavior 
of unloaded and mRNA-loaded microbubbles using contrast-enhanced ultrasound imaging after 
subcutaneous injection in dogs. Our results indicate that both types of microbubbles are equally 
capable of rapidly entering the lymph vessels and nodes upon injection, and novel, valuable and 
detailed information on the lymphatic structure in the animals could be obtained. Furthermore, 
additional observations were made regarding the dynamics of microbubble lymph node uptake. 
Importantly, neither the microbubble migration distance within the lymphatics, nor the observed 
contrast signal intensity was influenced by mRNA-loading. Although further optimization of 
acoustic parameters will be needed, this could represent a first step towards ultrasound-guided, 
ultrasound-triggered intranodal mRNA delivery using these theranostic microbubbles. 
Key words: Contrast-enhanced ultrasound imaging, mRNA, microbubbles, mRNA-loaded mi-
crobubbles, dogs, lymph nodes. 
Introduction 
Over the years, microbubbles have gained pop-
ularity as contrast agents for ultrasound imaging. 
When injected intravenously, these microbubbles re-
main within the vasculature where they increase the 
echogenicity of blood. In this way, enhanced contrast 
between blood and soft tissues can be achieved. This 
has led to the FDA and EMEA approval of various 
microbubble contrast agents for echocardiography 
(e.g. DefinityTM, SonoVueTM, SonazoidTM and Opti-
sonTM) [1]. Ever since, new applications for these con-
trast agents are under investigation, including their 
potential to enhance contrast in the lymphatics. For 
this, the microbubbles are injected intradermally (i.d.) 
or subcutaneously (s.c.), after which they drain to the 
lymphatics and accumulate in the lymph nodes. This 
is particularly interesting, since studies in tu-
mor-bearing animals as well as in human breast can-
cer patients showed that peritumoral i.d. and s.c. in-
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jection of microbubbles results in their drainage to the 
sentinel lymph node (SLN) [2-7]. This lymph node is 
especially important, as it is the first node to come in 
contact with tumor material, making it most vulnera-
ble to metastasis. Therefore, SLN detection, biopsy 
and removal are routine procedures in oncology to 
detect and remove disseminated tumor cells [8, 9]. 
Currently used standard methods for SLN detection 
are the injection of blue dyes which aid to localize the 
SLN visually during surgery, or via scintigraphy after 
injection of radiolabeled dyes [8, 10]. However, these 
procedures both come with their limitations, resulting 
in an ongoing search for novel SLN mapping modali-
ties, such as microbubble contrast-enhanced ultra-
sound imaging (CEUS), which could represent a 
non-radioactive, non-invasive and potentially more 
patient-friendly alternative [11, 12].  
In addition to these clinical applications, mi-
crobubbles are also under preclinical investigation as 
potential drug- and gene-delivery agents. When mi-
crobubbles are exposed to ultrasound, their gas core 
starts cavitating, i.e. it continuously expands and 
shrinks. When the amplitude of the applied ultra-
sound waves is augmented this cavitation can become 
unstable, eventually causing the microbubbles to im-
plode. Both stable cavitation as well as microbubble 
implosion can affect neighboring cells by either stim-
ulating endocytosis or by the formation of temporary 
pores in the cell membranes (i.e. sonoporation) [13]. 
Both mechanisms can be used for ultra-
sound-triggered delivery of drugs and genes in vitro 
and in vivo [14-16].  
Based on this knowledge, we recently reported 
on the design of microbubbles that can be loaded with 
mRNA-nanoparticles and have potential applications 
in cancer immunotherapy [17, 18]. For this, we 
showed that such mRNA-loaded bubbles could be 
used to induce transient protein-expression in murine 
dendritic cells (DCs). These cells are important targets 
in immunotherapy, as they are the key initiators of 
antigen-specific immune responses [19]. Therefore, by 
introducing tumor antigen expression in DCs, these 
cells can present fragments of these tumor antigens to 
T cells, leading to antigen-specific T cell activation 
[19-21]. In this way, the immune system can be stim-
ulated to selectively recognize and destroy cancer 
cells [18]. Although the clinical results are encourag-
ing, DC-based vaccination still needs to overcome a 
number of hurdles, one of which is the efficient de-
livery of antigenic material to the cells [22]. More 
specifically, current methods in the production of 
DC-based vaccines still focus on the ex vivo loading of 
these cells with tumor antigens, which makes 
DC-based immunotherapy time-consuming, pa-
tient-specific and expensive [23, 24]. Thus, there is an 
unmet need for methods that could deliver antigens to 
DCs in vivo. For this, the anatomical sites of interest 
would be lymphoid organs, such as the lymph nodes, 
as these harbor large numbers of DCs [25, 26]. There-
fore, we designed microbubbles that can be loaded 
with antigen mRNA, and were shown to efficiently 
transfect DCs in vitro [17]. Moreover, when these 
mRNA-sonoporated DCs were injected as vaccines in 
tumor-bearing mice, this resulted in the induction of 
potent antitumor immune responses, even leading to 
complete tumor regression and long-term immuno-
logical protection against tumor regrowth in 30% of 
the vaccinated animals [18]. Taken together, this 
strategy has shown promise in vitro, and could also 
have potential for immediate in vivo applications. 
More specifically, if these microbubbles could reach 
the lymphatics after s.c. injection, they could serve as 
interesting agents for the ultrasound-guided and ul-
trasound-triggered antigen delivery to intranodal 
DCs.  
To evaluate whether the proposed 
mRNA-loaded microbubbles could be used for this 
purpose, we investigated if indeed these nucleic-acid 
loaded bubbles can reach the lymph nodes after s.c. 
injection, and if this can be monitored with CEUS. For 
this, we performed a cross-over study where both 
unloaded and mRNA-loaded microbubbles were in-
jected subcutaneously in dogs. Using CEUS, we de-
termined (a) which injection site resulted in optimal 
lymphatic microbubble appearance, (b) if there were 
differences in kinetics and lymph node con-
trast-enhancement for both types of microbubbles and 
(c) to what extent the nucleic acid-loaded microbub-
bles could have potential as intralymphatic 
theranostics.  
Materials and methods 
mRNA and mRNA-lipoplexes 
Luciferase mRNA was produced by in vitro 
transcription from pBlue-Luc-A50 plasmids. The 
plasmids were purified using a QIAquick PCR puri-
fication kit (Qiagen, Venlo, The Netherlands) and 
linearized using Dra I restriction enzymes (Promega, 
Leiden, The Netherlands). Linearized plasmids were 
used as templates for the in vitro transcription reaction 
using the T7 mMessage mMachine kit (Ambion, Life 
Technologies, Ghent, Belgium). The resulting capped 
and polyadenylated mRNAs were purified by 
DNase I digestion, LiCl precipitation and washed 
with 70% ethanol. The mRNA concentration was de-
termined by measuring the absorbance at 260 nm. 
mRNA was stored in small aliquots at -80°C at a con-
centration of 1 µg µl-1.  
mRNA lipoplexes were prepared by complexing 
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the mRNA to cationic liposomes. For this, liposomes 
were prepared consisting of 48.75% DOTAP (1,2- 
dioleoyl-3-trimethylammonium-propane), 48.75% 
DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanola-
mine, both Avanti Polar Lipids) and 2.5% 
DSPE-PEG3400-biotin [1,2-distearoyl-sn-glycero-3- 
phosphoethanol-amine-N-[biotinyl(polyethylenegly-
col)-3400] (Laysan Bio Inc, Arab, Alabama). Fluores-
cently labeled mRNA-lipoplexes were prepared by 
incorporating 1% Cholesteryl-BODIPY® FL C12 
(Avanti Polar Lipids). The appropriate amounts of 
lipids (dissolved in chloroform) were transferred to a 
round-bottom flask, and the chloroform was evapo-
rated under nitrogen. Subsequently, the resulting li-
pid film was hydrated in RNase-free water (Ambion) 
to obtain a final lipid concentration of 1 mg ml-1. The 
resulting cationic liposomes were sonicated for 15min 
in a bath sonicator (Branson Ultrasonics, Dansbury, 
USA). Then, the cationic liposomes were mixed with 
mRNA in OptiMem® (Gibco Invitrogen) to obtain 
mRNA-lipoplexes at a cationic lipid-to-mRNA charge 
(N/P) ratio of 8. 
Unloaded and mRNA-loaded microbubbles 
Lipid microbubbles loaded with 
mRNA-lipoplexes were prepared as described pre-
viously [17]. Briefly, perfluorobutane (F2 chemicals, 
Preston, UK) microbubbles stabilized by a lipid coat 
consisting of DPPC (1,2-dipalmitoyl-sn-glycero- 
3-phosphocholine) (Lipoid, Ludwigshafen, Germany) 
and DSPE-PEG3400-biotin [1,2-distearoyl-sn-glycero- 
3-phosphoethanolamine-N-[biotin(polyethylene gly-
col)-3400] in a 85:15 molar ratio were prepared as fol-
lows. Appropriate aliquots of both lipids, dissolved in 
chloroform, were transferred to a round bottom flask. 
After chloroform evaporation, the lipids were dis-
solved in a 1:2:7 glycerol-propyleneglycol-H2O mix-
ture to obtain a clear solution with a final concentra-
tion of 4.6x10-4 mmol ml-1. Aliquots of this lipid solu-
tion were transferred to 2.5 ml chromatography vials 
and the vial headspace was filled with perfluorobu-
tane gas (F2 chemicals, Preston, UK). In order to form 
microbubbles, the vials were shaken at 
high-frequency in a Capmix™ device (3M-ESPE, 
Diegem, Belgium) for 15s. Microbubbles were avi-
dinylated by first performing washing steps to re-
move excess lipids, after which the microbubbles 
were incubated with avidin (Cell Sciences, Canton, 
USA) for 5min. Then, the bubbles were washed to 
remove excess avidin and the final bubble cake was 
redispersed in a sterile, endotoxin- and nuclease-free 
5% glucose solution (Sigma-Aldrich, Diegem, Bel-
gium). 5min prior to injection, 150 µl avidinylated 
bubbles were mixed with either 100 µl OptiMem® (for 
the unloaded bubbles) or 100 µl mRNA-lipoplexes 
(for the mRNA-loaded microbubbles, corresponding 
to 10 µg mRNA per injection).  
Microbubble characterization 
The size distribution and concentration of 
mRNA-loaded microbubbles was determined via 
coulter counter measurements using a Beck-
man-coulter Multisizer 4 (Analis SA, Suarlée, Bel-
gium). Confocal microscopy was performed to evalu-
ate the loading of the microbubbles with fluorescently 
labeled mRNA-lipoplexes. This was done using a 
Nikon C1si confocal laser scanning module attached 
to a motorized Nikon TE2000-E inverted microscope 
(Nikon, Brussels, Belgium), and a Plan Apo 60X 1.4 
NA oil immersion objective lens (Nikon). 
Dogs 
Six healthy research beagles (3 spayed females, 1 
intact female and 1 castrated male and 1 intact male) 
were used in this experiment. All procedures were 
performed in accordance with the Ethical committee 
guidelines of the Ghent University (2014/31). The 
mean age of the animals was 7 years. Body weight 
ranged from 9.7 kg to 15.4 kg with a mean of 10.8 kg. 
Dogs were healthy based on physical findings and 
routine laboratory data. 
Contrast-enhanced ultrasound imaging 
For CEUS experiments, the animals were sedat-
ed by intravenous injection of a combination of Bu-
torphanol (Dolorex, 0.4 mg kg-1) and Acepromazine 
(Placivet, 0.04 mg kg-1). Once sedated, the animals 
were manually restrained in dorsal recumbency and 
received a subcutaneous injection of microbubbles. 
First, different injection sites in the caudal abdomen 
and inguinal region were evaluated based on contrast 
migration to choose the optimal location for further 
experiments. After injection of 250 µl microbubbles, 
the contrast timer was started and the injection site 
was massaged during 1min. After this, continuous 
CEUS imaging was performed with contrast-specific 
software using a 12-5 MHz linear transducer (L12-5) 
of a Philips iU-22 US scanner (Philips Medical sys-
tems, Bothell, Wa) for at least 6min. Mechanical index 
(MI) was set at a low level (MI=0.08) to achieve mi-
crobubble resonance with production of harmonic 
frequencies. Machine settings such as the overall gain 
(80%), time gain compensation, depth (2.5 cm), frame 
rate (10 Hz) persistence (off) and dynamic range were 
set at the same value for every examination. Only one 
focal spot was used, and was set at the lowest level of 
the image. Destruction of intranodal microbubbles 
was performed at the end of the imaging period by 
setting the acoustic power at the highest level 
(MI=0.61). Multiple subsequent bursts were delivered 
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until the echo intensity stabilized.  
This study was performed using a crossover de-
sign, with all dogs receiving 2 injections of both un-
loaded and mRNA-loaded microbubble formulations, 
on two injection sites (in the left and right abdominal 
region) at 2 different time points separated by a 2 
week wash-out period, resulting in a total of 24 injec-
tions (12 with unloaded bubbles and 12 with 
mRNA-loaded bubbles, Table 1).  
 
Table 1: Design of the crossover CEUS study.  
Day Dogs Microbubble injections 
Week 1, day 1 1, 2, 3 Left: unloaded microbubbles 
Right: mRNA-loaded microbubbles 
Week 1, day 2 4, 5, 6 Left: mRNA-loaded microbubbles  
Right: unloaded microbubbles 
2 week wash-out   
Week 3, day 1 1, 2, 3 Left: mRNA-loaded microbubbles  
Right: unloaded microbubbles 
Week 3, day 2 4, 5, 6 Left: unloaded microbubbles 
Right: mRNA-loaded microbubbles 
 
 
Image analysis 
Image analysis was performed using QLAB 
quantification software (Philips) and ImageJ. Mi-
crobubble migration distances were calculated as a 
linear distance between the injection site and the most 
distant microbubble contrast signal. Measurements 
were performed by two independent, blinded ob-
servers. Maximal echo intensities were measured us-
ing ImageJ at different timepoints after injection on a 
region of interest (ROI) within the lymphatics (i.e. 
within the enhanced lymph nodes or within the 
lymph vessels when no lymph node enhancement 
could be observed). Analysis of burst destruction of 
intranodal microbubbles was performed by drawing a 
ROI over the lymph node of interest, after which the 
mean echo intensity was studied as a function of time 
using the QLAB quantification software. In the fig-
ures, time is indicated in min:s on the CEUS images, 
and the depth scale bar is shown at the right-hand 
side of the corresponding B-mode images (the dis-
tance between two ticks is 5 mm in all images). 
Statistical analysis 
The migration distance and the maximal echo 
intensity was compared between the loaded and un-
loaded bubbles by a mixed model with dog as random 
effect and period and bubble type as categorical fixed 
effects, using the F-test at the 5% significance level. 
The contrast echo intensity over time was compared 
between the loaded and unloaded bubbles by a mixed 
model with dog as random effect and period, time, 
bubble type and the interaction between time and 
bubble type as categorical fixed effects, using the 
F-test at the 5% significance level. 
Within and between observer variability was 
determined by estimating the within and between 
observer variances for a same assessment (i.e., the 
same dog, side, bubble type and period) by the re-
stricted maximum likelihood procedure (REML). 
These estimated variances were next used to deter-
mine the range in which 95% of the differences be-
tween two measurements of the same observers and 
two different observers are contained. SAS version 9.3 
was used for all analyses. 
Results 
Characterization of unloaded and 
mRNA-loaded microbubbles 
mRNA-lipoplex loaded microbubbles were 
prepared by first complexing the mRNA to cationic 
liposomes, to form mRNA-lipoplexes in which the 
mRNA is protected against degradation (Additional 
file 5: Figure S1). These mRNA-lipoplexes are then 
attached to the surface of avidinylated lipid mi-
crobubbles, as shown in Figure 1A. To demonstrate 
effective loading, we performed confocal microscopy 
on microbubbles that were loaded with fluorescently 
labeled mRNA-lipoplexes. As demonstrated in Fig-
ure 1B, the mRNA-lipoplexes are clearly present 
around the microbubble surface, and we did not ob-
serve any aggregation. The size and concentration of 
the microbubble preparations was determined via 
coulter counter measurements. The unloaded mi-
crobubbles had a mean number diameter of 
2.48 ± 1.57 µm. Attachment of mRNA-lipoplexes did 
not significantly alter the mean diameter 
(1.93 ± 1.25 µm) (Figure 1C). The concentration of the 
microbubble preparations was 2.68 ± 0.86 x 109 bub-
bles ml-1.  
Factors influencing intralymphatic CEUS 
Based on previous experiments studying the 
lymphatic drainage of SonoVueTM microbubbles by 
Goldberg et al. [7], we performed subcutaneous injec-
tions of both unloaded and mRNA-loaded microbub-
bles in dogs. When performing these experiments, we 
observed that a number of factors influenced the 
CEUS signals.  
First of all, we noticed important differences in 
the migration of the microbubbles depending on the 
location of the injection site. When injecting the mi-
crobubbles in the groin, close to the inguinal lymph 
node, we could not observe any lymphatic uptake of 
the contrast agents. The reasons for this are probably 
dual. First of all, lymphatic uptake occurs through a 
passive process that depends on the interstitial pres-
sure at the injection site. Hence, regions such as the 
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groin, where the skin is loose and the interstitial 
pressure is low, are not preferable [27]. In addition to 
pressure-related differences, some tissues, such as the 
mammary regions of female dogs, contain a more 
developed lymph vessel network. In accordance to 
this, initial s.c. injections of the contrast agents in the 
loose skin of the abdominal region did not result in 
migration of the contrast agents from the injection 
site. This despite the fact that the microbubbles were 
injected at a distance of merely 20 mm from the in-
guinal lymph node, as indicated by palpation and 
B-mode ultrasound imaging. On the other hand, in-
jection around the dog’s nipple resulted in extensive 
microbubble drainage in all female dogs, as shown in 
Figure 2. Migration from the injection site was seen 
for all injections with both unloaded (8/8) and 
mRNA-loaded (8/8) microbubbles in the female dogs, 
and after most of the injections around the nipples of 
the male dogs (4/4 for the unloaded bubbles and 2/4 
for the mRNA-loaded bubbles). This is not unex-
pected, as the mammary regions accommodate a vast 
network of lymph vessels that lead to multiple clus-
ters of lymph nodes close to the mammary glands, as 
well as more distant gastric and mesenteric lymph 
nodes, depending on the location of the mammary 
gland (e.g. axillary versus inguinal mammary glands) 
[28]. Based on these observations, further injections 
were performed s.c. around the left and right nipple 
of the inguinal mammary gland. 
 
 
Figure 1: Characterization of mRNA-loaded microbubbles. (A) Graphical representation of the mRNA-loaded microbubble composition. (B) Confocal microscopic 
images of microbubbles loaded with fluorescently labeled mRNA-lipoplexes: (B1) transmission, (B2) green fluorescent mRNA-lipoplexes, (B3) overlay. (C) Size distribution of 
unloaded and mRNA-loaded microbubbles. 
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Figure 2: Influence of animal properties on the lymphatic CEUS images. Pictures show the CEUS images obtained after s.c. injection of unloaded microbubbles around 
the mammary glands of a male dog (A1), a spayed female dog (B1) and an intact female dog (C1). Respective B-mode images are shown in A2, B2 and C2. The injection site is 
indicated as “i.s.” (the injection site for images C1 and C2 is out of the field-of-view), arrows indicate the accumulation of microbubbles in the lymph nodes and lymph vessels are 
pointed out with asterisks. Time after microbubble injection is noted on the CEUS images (in min:s). 
 
Besides the effects of the injection site, in-
ter-animal variation in the mammary gland lymphatic 
network also played a role. In male dogs, the mam-
mary glands are markedly less developed compared 
to females, which also results in a less dense lym-
phatic network and fewer intramammary nodes. 
Moreover, the male dogs clearly showed a less thick 
subcutaneous fat layer (i.e. where the lymph vessels 
and nodes are located) compared to all females, as 
evidenced by the B-mode images in Figure 2, images 
A2, B2 and C2. As a result, contrast agent migration 
after injection was less pronounced in the males 
compared to the females. In the intact male, injection 
next to the testicles resulted in more distant mi-
crobubble migration when compared to injection 
around the mammary glands, which therefore repre-
sented a valuable alternative to injection around the 
mammary glands. Beside these gender-related factors, 
we also observed differences between spayed and 
intact females. After microbubble injection in the in-
tact female, the lymphatic structures were visible as a 
vast network with multiple nodes and vessels ex-
tending more deeply into the subcutaneous fat pad 
(Figure 2, images C1 and C2, and Additional file 1: 
supplementary video 1, observed for all injections 
with both unloaded and mRNA-loaded microbub-
bles). Such a branched lymph network could not be 
observed in any of the 3 spayed females.  
Of course, this inter-animal variation makes it 
more difficult to fully exclude anatomical bias when 
comparing the lymphatic drainage of unloaded and 
mRNA-loaded microbubbles. The cross-over design 
used for this study, where all dogs receive s.c. injec-
tions with both unloaded and mRNA-loaded mi-
crobubbles in the nipples of both the left and the right 
caudal mammary gland, was used to take this varia-
bility into account and allow a better comparison of 
both microbubble types.  
Lymphatic network visualization 
After microbubble injection and massaging of 
the injection site, the migration of the contrast agent 
was observed unidirectional, with the contrast agents 
leaving the injection site at only one end in the spayed 
females and the males, as exemplified by Figure 3A. 
In the intact female, microbubble migration occurred 
both cranially as well as caudally. The migrating con-
trast agents were followed through the lymph vessels 
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towards draining lymph nodes (Figure 3, Images B1, 
B2, C1 and C2, and Additional file 2: supplementary 
video 2). Importantly, in none of the injections (0/24) 
did we observe blood pool contrast enhancement, 
indicating that the microbubbles were restricted to the 
interstitium, the lymph vessels and the lymph nodes. 
Moreover, when the contrast agents were injected on 
one side (either left or right) of the animal, contrast 
signal was only observed on that same side of the 
animal. We did not observe contrast crossing over the 
midline of the dogs in any of the cases. One or multi-
ple lymph nodes could be identified using CEUS after 
9/12 injections of both unloaded and mRNA-loaded 
microbubbles, and the size of the enhanced lymph 
nodes ranged from 1.6 to 7.0 mm.  
Interestingly, CEUS imaging revealed rather 
detailed information on the lymphatics’ anatomy: in 
accordance to previous reports, CEUS could provide 
information on the location of the lymph nodes, the 
number of afferent and efferent lymph vessels [5]. In 
addition, we could observe different patterns of con-
trast agent presence within the nodes. Some lymph 
nodes, such as the one shown in Figure 4A, are com-
pletely filled with contrast agent, whereas others ra-
ther exhibit a “hollow” appearance, with contrast 
material only appearing at the outer rim of the node, 
as shown in Figure 4, images B1, B2, C1 and C2. This 
can be explained by the fact that afferent lymph ves-
sels can either directly discharge their content into the 
draining lymph nodes, or the afferent lymph vessels 
run through or over the nodes, without effectively 
discharging the lymph within the node [29].  
 
 
Figure 3: Contrast agent migration from the injection site into the lymph vessels and nodes. Upon microbubble injection, unidirectional transport of microbubbles 
away from the injection site, through an afferent lymph vessel into a draining lymph node can be observed with CEUS (A1). Image (B1) shows the trafficking of microbubble 
contrast signal through branched lymph vessels. In (C1), the CEUS image shows a lymph node connected to one afferent lymph vessel and 3 efferent lymph vessels that take the 
contrast agents further away from the injection site. Corresponding B-mode images are shown in (A2), (B2) and (C2), respectively. Images were obtained after injection of 
mRNA-loaded microbubbles in different female dogs. The injection site is marked as “i.s.” (unless outside of the field-of-view), arrows indicate lymph nodes and asterisks point 
out lymph vessels. Time after microbubble injection is noted on the CEUS images (in min:s). 
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Figure 4: Lymph node anatomy observed by CEUS. CEUS can be used to identify the relation between afferent lymph vessels and draining lymph nodes. Lymph vessels 
either distribute their content within the lymph node (“filled” nodes, A1-A2) or they go around the lymph nodes without discharging its contents into the node (“hollow” nodes, 
B1-B2 and C1-C2). In the latter scenario, we always observed a node with a “hollow” appearance (indicated as “H”), followed by a more distant “filled” node (indicated as “F”). 
Images were obtained from 3 different animals. Where possible, the injection site is pointed out as “i.s.”. Time after microbubble injection is noted on the CEUS images (in min:s). 
 
Lymphatic CEUS using mRNA-loaded 
microbubbles versus unloaded microbubbles 
In this study, we compared the CEUS images 
after s.c. injection of unloaded and mRNA-loaded 
microbubbles, using three main scoring criteria: (a) 
the migration distance of the contrast agents from the 
injection site within the lymphatics, (b) the maximal 
intensity of the contrast signal and (c) the stability of 
the contrast agents in the lymph vessels and nodes 
over time.  
With regards to the first parameter, the migra-
tion distance, we could detect microbubble migration 
from the injection site for all injections with unloaded 
microbubbles (12/12), and in 10/12 cases after 
mRNA-loaded microbubble injections. The 2 injec-
tions that did not result in contrast agent drainage 
were observed in the male dogs (1 in the castrated 
male and 1 in the intact male). The microbubble mi-
gration distance (calculated linearly from the injection 
site) was on average 24.7 ± 13.7 mm for unloaded mi-
crobubbles and 29.0 ± 19.0 mm for mRNA-loaded 
microbubbles (Figure 5A). No significant difference 
was observed for migration distance between the 
loaded and unloaded bubbles, with a mean difference 
equal to 4.33 (95% CI: [-4.55; 13.22]). It should be noted 
that even though these results were analyzed based 
on injections of unloaded and mRNA-loaded mi-
crobubbles within the same mammary gland, varia-
tion based on the exact injection site cannot be ex-
cluded, even though injections were always per-
formed caudally from the nipple by the same person. 
For instance, it was shown by Goldberg et al. [6] that 
injection sites that were merely 1 cm apart in distance, 
could result in drainage to a different lymph node, 
which can obviously impact the microbubble migra-
tion distance that was observed. As the exact injection 
site was not marked at the time of the first imaging 
session, variation related to the injection site location 
cannot be fully excluded. The variation between re-
peated observations of the same observer was 23.9, 
and the extra variation due to different observers was 
9.0 for loaded bubbles, leading to somewhat larger 
95% intervals for differences between two measure-
ments of two different observers as compared to the 
same observer. On the other hand, for the unloaded 
microbubbles, the variation due to repeated observa-
tions of the same observer was 16.7, and there was no 
extra variation due to different observers, resulting in 
the same 95% intervals for differences between two 
measurements of two different observers as compared 
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to the same observer (Additional file 5: Figure S2). 
In addition to distance measurements, we com-
pared the maximal echo intensity that we could obtain 
within the lymphatics after injection of unloaded and 
mRNA-loaded microbubbles. As for the migration 
distance, we could observe no significant differences 
in lymphatic contrast enhancement between both 
types of bubbles (Figure 5B), with a mean difference 
between loaded and unloaded bubbles equal to -2.56 
(95% CI:[-15.04; 9.91]). Moreover, when the contrast 
echo intensity was evaluated as a function of time, we 
could observe relatively long-term contrast agent sta-
bility within the lymphatics, as in all cases where 
contrast migration was observed, the microbubbles 
could still be clearly detected 6min after microbubble 
injection (Additional file 3: Supplementary video 3). 
There was merely a slight decay of the echo intensity 
over this period, and we could not detect significant 
differences between both types of microbubbles (Fig-
ure 6).  
Keeping in mind the final aim of the mRNA 
loaded microbubbles, namely the ultra-
sound-triggered delivery of mRNA to DCs that reside 
within the lymph nodes, we tested whether intranod-
al mRNA-loaded microbubbles could indeed be im-
ploded by applying higher-intensity ultrasound 
bursts. For this, we used the scanner’s preset burst 
function, and looked at the decrease in mean echo 
contrast intensity within the lymph node. As shown 
in Figure 7, with each burst, the microbubble echo 
intensity was reduced, reaching a minimum after 6 
bursts. A video of this burst destruction can be found 
in supplementary data (Additional file 4: supple-
mentary video 4).  
 
 
Discussion 
In recent years, drug- and gene loaded mi-
crobubbles emerged as interesting theranostics after 
intravenous injection. This, however, is the first report 
on the development of theranostic mRNA-loaded 
microbubbles for lymphatic imaging and lymph node 
detection after s.c. injection. When taken together with 
our previous research on transfections with these mi-
crobubbles, this paves the way for ultrasound-guided 
microbubble-assisted drug delivery to intranodal 
cells. To explore this, we aimed to compare unloaded 
and mRNA-loaded microbubbles with respects to the 
lymphatic uptake and contrast enhancement in the 
lymph nodes upon s.c. injection in dogs.  
 
 
Figure 5: Maximal migration distance and maximal echo intensity of mRNA-loaded and unloaded microbubbles. Scatterplots show (A) the linear migration 
distance of unloaded and mRNA-loaded microbubbles from the injection site and (B) the maximal echo intensities within the lymphatics for both microbubble types. For both 
parameters, no statistically significant differences between unloaded and mRNA-loaded microbubbles could be detected. 
 
 
Figure 6: Intralymphatic stability of mRNA-loaded and unloaded microbubbles. The maximal echo intensity was followed as a function of time for both unloaded and 
mRNA loaded microbubbles. A slow reduction in maximal echo intensity was observed over the 6min imaging period. No significant differences could be detected between 
unloaded and mRNA-loaded microbubbles. 
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Figure 7: Burst destruction of intranodal microbubbles. After visualization of unloaded microbubble drainage, the scanner’s burst function was used to destroy the 
microbubbles within the lymphatics. Images show (A) CEUS image with a ROI drawn around a lymph node filled with mRNA-loaded microbubbles and (B) the corresponding 
B-mode image. Burst analysis is represented in (C) as the echo mean (dB), where each burst is visible as an echo mean peak, followed by a reduction of the contrast echo mean. 
Time after mRNA-loaded microbubble injection is noted on the CEUS images (in min:s). 
 
The lipid microbubbles used in this study could 
be efficiently loaded with mRNA-lipoplexes, and had 
mean diameters around 2.5 µm, which is comparable 
to the size of commercially available microbubbles. 
Lipoplex-loading did not significantly alter the mean 
microbubble diameter. Our imaging results indicated 
that despite animal-related variation, both types of 
microbubbles could be detected within the lymph 
nodes within 1min after s.c. injection around the 
mammary glands. How exactly the microbubbles are 
transported from the interstitium to the lymph vessels 
remains controversial, as it goes against the current 
view of ideal particle properties for lymphatic uptake. 
It is generally considered that particles between 10 
and 100 nm in size result in the best lymphatic uptake 
[27]. Although the appearance of 1 µm particles in the 
draining lymph nodes was also observed, their uptake 
efficiency and speed was significantly reduced and a 
large fraction of the injected particles were retained at 
the injection site [30]. In the case of our microbubbles 
we could observe fast and extensive microbubble up-
take into the lymph vessels and draining nodes, de-
spite their larger size. The rapid uptake of microbub-
bles into the lymphatic system is not well understood. 
A first explanation could be found within the other 
physicochemical properties of the microbubble con-
trast agents we injected. Besides particle size, lipo-
philicity and the presence of surface modifications 
that give stealth properties to injected particles, were 
also reported to positively impact their lymphatic 
drainage [30]. Therefore, the presence of the lipid coat 
in both the microbubbles and the mRNA-lipoplexes 
could aid to promote microbubble uptake into the 
lymph vessels. In addition, the microbubbles as well 
as the mRNA lipoplexes contain lipids that are con-
jugated to polyethylene glycol (PEG, 15 mol.% and 
2.5 mol.% for bubbles and lipoplexes respectively), 
which is known to protect the particles against uptake 
by phagocytes, thus reducing their premature clear-
ance, resulting in enhanced drainage to the lymphat-
ics. On the other hand, Goldberg et al. proposed a 
cell-mediated uptake mechanism after s.c. injection of 
SonazoidTM in pigs [6]. They performed electron mi-
croscopy on isolated lymph nodes after contrast agent 
injection, and observed the presence of vacuoles in the 
intranodal phagocytic cells, which could imply that 
the microbubbles are first ingested by cells, which 
then transport them from the interstitium to the 
lymph vessels and draining lymph nodes. However, 
this cellular transport through the lymphatics is only 
likely for microbubbles that are easily phagocytosed. 
A study by Yanagisawa pointed out that microbubble 
phagocytosis by primary liver cells was highly de-
pendent on the microbubble composition. Indeed, the 
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authors demonstrated that over 99% of the Sonazoid 
microbubbles were rapidly phagocytosed by primary 
liver cells, which can likely be attributed to their shell 
composition [31]. SonazoidTM consists of egg phos-
phatidyl serine, which is recognized by macrophages 
and thus enhances phagocytic uptake [32, 33]. In con-
trasts, anionic ImavistTM microbubbles (where the 
anionic charges reduce microbubble contact with cell 
membranes) and PEGylated SonoVueTM microbubbles 
were merely for 0% or 7.3% phagocytosed, respec-
tively. As our microbubbles are also PEGylated (by 
inclusion of 15% DSPE-PEG (3400)-biotin), and no 
specific targets for macrophage recognition are pre-
sent, it is unlikely that our microbubbles were carried 
into the lymphatics inside of cells.  
Upon s.c. injection, we could observe clear mi-
gration of both unloaded and mRNA-loaded mi-
crobubbles from the injection site into the lymph ves-
sels and the draining lymph nodes. Moreover, our 
CEUS images nicely correspond to previous reports 
on the lymphatic drainage of microbubbles, which 
indicates that the observed structures were indeed 
lymph nodes [5-7, 34, 35]. The imaging options that 
are associated with these mRNA-loaded microbub-
bles could have implications for mRNA delivery as 
well as for diagnostic purposes. Firstly, the 
mRNA-loaded microbubbles could provide infor-
mation on the anatomical features of draining lymph 
nodes. To our knowledge, this is the first report where 
CEUS was shown to discriminate between the two 
different types of connection of lymph vessels to 
lymph nodes (i.e. the “hollow” nodes and the “filled” 
lymph nodes) [29]. The impact of this might be dual. 
First of all, from our perspective of future mRNA de-
livery to intranodal DCs, it would be a major ad-
vantage to be able to discriminate between situations 
where the afferent lymph vessels discharge the 
mRNA-loaded bubbles within the core of the lymph 
node (“filled” nodes) versus lymph vessels that 
merely run over the surface of the lymph nodes, thus 
bypassing the actual node, resulting in the absence of 
a microbubble signal in the center of the node (“hol-
low” nodes). Only in the first scenario will the 
mRNA-loaded bubbles be able to reach the intranodal 
DCs, and is DC transfection with mRNA via sono-
poration possible. Therefore, delivery of 
high-intensity ultrasound pulses to induce microbub-
ble implosion and mRNA delivery should only be 
performed in the lymph nodes that exhibit the “filled” 
appearance. Other than for ultrasound-guided drug 
delivery, this anatomical information could also have 
benefits with regards to SLN detection. In a tumor 
setting, the SLN will be the first lymph node that en-
counters material that directly originates from the 
tumor, such as disseminating tumor cells. However, if 
the first lymph node after the tumor has the “hollow” 
characteristics, this means that the tumor cells do not 
enter within the node, making it less likely that this 
node would be populated with tumor cells [29]. 
Therefore, lymph node biopsies to detect lymph node 
metastasis are best performed in the first node in 
which the content of the tumor-draining lymph ves-
sels are actually discharged. CEUS-guided identifica-
tion of the first “filled” SLN could therefore have an 
added value to reduce chance of false negatives in 
SLN biopsies. Of note, other imaging possibilities 
such as 3D CEUS imaging, could enable improved 
visualization of the lymphatic drainage and improve 
variability in measurements. 
When comparing mRNA-loaded microbubbles 
with unloaded microbubbles, we could not observe 
statistically significant differences with regards to 
migration distance, mean contrast intensity and the 
stability of both contrast agents in the lymphatics. As 
the size distribution of both types of bubbles did not 
significantly differ, this was not entirely unexpected. 
In addition, experiments on similar nanoparti-
cle-loaded lipid microbubbles by Luan et al. demon-
strated that the shell elasticity of individual unloaded 
and liposome-loaded microbubbles was nearly the 
same [36]. The effects of liposome-loading that was 
observed by the authors were mainly on the mi-
crobubble shell viscosity (which was higher for lipo-
some-loaded microbubbles) and thus on the ultra-
sound-induced microbubble vibrations. Taken to-
gether, the impact on these acoustical differences 
between two types of bubble populations is expected 
to be limited with respect to contrast-enhancement. 
However, it is likely that for molecular imaging and 
therapeutic purposes, which often involve only a sin-
gle microbubble or a few microbubbles in a given 
volume, these differences will need to be addressed: 
liposome-loaded microbubbles exhibited a higher 
pressure threshold for microbubble vibration, which 
might indicate that the pressures that will be needed 
to implode these bubbles in order to locally deposit 
the mRNA, also need to be higher. This could already 
be expected based on the burst-destruction of the in-
tranodal mRNA-loaded microbubbles. Using the 
preset “burst” function on the clinical scanner, the 
microbubble contrast signal is maximally reduced by 
50%, indicating an incomplete intranodal microbub-
ble destruction. Only after 6 bursts the mean echo 
reaches a minimum. On this basis, the transducer that 
was used in this study (12-5 MHz linear) is likely not 
ideal for microbubble destruction that could allow 
effective sonoporation and mRNA transfection. Other 
clinical transducers that can emit lower frequencies, 
which are closer to the resonance frequency of the 
microbubbles and can emit higher powers, could be 
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better suited. In any case, optimization of the various 
ultrasound parameters such as acoustic pressure, 
pulse duration and number of pulses, will be required 
for this purpose [13].  
Conclusion 
In conclusion, we were able to show that 
homemade unloaded as well as mRNA-loaded mi-
crobubbles efficiently reach the lymph vessels and 
nodes upon subcutaneous injection in dogs. Loading 
of the microbubbles with mRNA-lipoplexes had no 
significant effect on the distance of microbubble mi-
gration from the injection site, nor on the intensity of 
the observed contrast signals. This shows that 
theranostic mRNA-loaded microbubbles could have 
potential for the ultrasound-guided, ultra-
sound-triggered intranodal delivery of mRNA. 
However, further research is needed for the optimi-
zation of acoustic parameters to most effectively 
sonoporate target cells of interest. 
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Supplementary Video 4: Burst destruction of intran-
odal microbubbles. After injection of unloaded mi-
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